// App-Quantinova.ai

685 : A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model

Researchers

Presenter

  • David Ciccone

Principal Investigators

  • Vad Lazari

  • Ian Linney

  • Michael Briggs

  • Samantha Carreiro

  • Joshua McElwee

  • Ian Waddell

  • Chris Hill

  • Christine Loh

  • Peter Tummino

  • Alan Collis

  • Neelu Kaila

Medical Centers

  • Charles River Laboratories, Chesterford Research Park, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved